LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).

被引：0
作者：
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Rambam Hlth Care Campus, Haifa, Israel
[3] Huntsman Canc Inst, Salt Lake City, UT USA
[4] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Merck & Co Inc, Rahway, NJ USA
[6] Westmead Hosp, Sydney, NSW, Australia
[7] Macquarie Univ, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4603
引用
收藏
页数：1
相关论文
共 50 条
[21]   Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort [J].
Strowd, Roy E. ;
De La Fuente, Macarena Ines ;
Bauer, Todd Michael ;
Papadopoulos, Kyriakos P. ;
Chen, Ke ;
Perini, Rodolfo F. ;
Liu, Yanfang ;
McDermott, David F. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22]   Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study [J].
Sheng, Xinan ;
Guo, Hongqian ;
Yao, Xin ;
Zhou, Fangjian ;
Chen, Jimin ;
Zhang, Shun ;
Li, Juan ;
Diao, Lei ;
Dong, Pei ;
Li, Xiaoqing ;
Zhang, Zhewei ;
Chain, Anne ;
Zhu, Pengfei ;
Zhang, Weijuan ;
Wang, Ding ;
Guo, Jun .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23]   Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort [J].
Jonasch, Eric ;
Bauer, Todd M. ;
Papadopoulos, Kyriakos P. ;
Plimack, Elizabeth R. ;
Merchan, Jaime R. ;
Mcdermott, David F. ;
Michaelson, M. Dror ;
Appleman, Leonard J. ;
Roy, Ananya ;
Perini, Rodolfo F. ;
Liu, Yanfang ;
Choueiri, Toni K. .
EUROPEAN JOURNAL OF CANCER, 2024, 196
[24]   Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up of the East Asian subgroup of the randomized phase III LITESPARK-005 trial [J].
Lee, J-L. ;
Park, S. H. ;
Kato, T. ;
Saika, T. ;
Masumori, N. ;
Oya, M. ;
Nishimoto, K. ;
Fujimoto, H. ;
Eto, M. ;
Kishida, T. ;
Lee, H. J. ;
Su, Y-L. ;
Miura, Y. ;
Matsubara, N. ;
Kitamura, H. ;
Cheng, A. C. K. ;
Xing, A. ;
Perini, R. ;
Vickery, D. ;
Rini, B. I. .
ANNALS OF ONCOLOGY, 2024, 35 :S1505-S1505
[25]   Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) [J].
Whorf, R. C. ;
Hainsworth, J. D. ;
Spigel, D. R. ;
Yardley, D. A. ;
Burris, H. A., III ;
Waterhouse, D. M. ;
Vazquez, E. R. ;
Greco, F. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26]   A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) [J].
Motzer, R. J. ;
Bhargava, P. ;
Esteves, B. ;
Al-Adhami, M. ;
Slichenmyer, W. ;
Nosov, D. ;
Eisen, T. ;
Sternberg, C. N. ;
Hutson, T. E. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[27]   Randomized phase iii trial of sorafenib in advanced renal cell carcinoma (RCC): Iimpact of crossover on survival [J].
Eisen, T. ;
Bukowski, R. ;
Staehler, M. ;
Szczylik, C. ;
S., Oudard ;
Stadler, W. ;
Simantov, R. ;
Shan, M. ;
Escudier, B. .
EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) :237-237
[28]   Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival [J].
Eisen, T. ;
Bukowski, R. M. ;
Staehler, M. ;
Szczylik, C. ;
Oudard, S. ;
Stadler, W. M. ;
Schwartz, B. ;
Simantov, R. ;
Shan, M. ;
Escudier, B. .
ANNALS OF ONCOLOGY, 2006, 17 :54-54
[29]   LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy [J].
Motzer, Robert J. ;
Schmidinger, Manuela ;
Eto, Masatoshi ;
Suarez, Cristina ;
Figlin, Robert ;
Liu, Yanfang ;
Perini, Rodolfo ;
Zhang, Yayan ;
Heng, Daniel Y. C. .
FUTURE ONCOLOGY, 2023, 19 (02) :113-121
[30]   Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC) [J].
Reinhardt, C. ;
Zdrojowy, R. ;
Szczylik, C. ;
Ciulenau, T. ;
Brugger, W. ;
Oberneder, R. ;
Kirner, A. ;
Walter, S. ;
Singh, H. ;
Stenzl, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345